Friday, May 4, 2012

Drug Discovery@nature.com 4 May 2012

Drug Discovery

Advertisement
Advance your cancer research with the xCELLigence System. Measure cell migration continuously using the CIM-Plate 16. For life science research only. Not for use in diagnostic procedures.

Visit: http://www.xCELLigence.roche.com
TABLE OF CONTENTS

4 May 2012

News
Analysis
Research Highlights
Research & Reviews
Careers
Advertisement


Transgenic Humanized HLA Mice


• for basic research into          human immune response
• for vaccine research and 
  development
• for immunogenicity testing 
  of protein therapeutics

No upfront fees or agreements to sign. 

Order now!


Nature Reviews Drug Discovery is on Twitter

Advertisement
Nature Reviews Cancer
POSTER - MITOCHONDRIAL FUNCTION AND CANCER
Author: Douglas C. Wallace

This Poster highlights some recent discoveries that have led to a renewed interest in the function of mitochondria in cancer cells. Mitochondria carry out a number of crucial functions in cells and these can be altered through mutations in either the nuclear DNA or the mitochondrial DNA.

Access the Poster FREE online!
www.nature.com/nrc/posters/mitochondria

This Poster is freely available thanks to sponsorship from
Abcam
 

News

Top

Anti-NGF painkillers back on track?
doi:10.1038/nrd3732
Following an FDA advisory committee vote to restart clinical development of nerve growth factor antagonists, could this novel class of analgesics still fulfil its once-anticipated potential?
Full Text

Oncology trials gear up for high-throughput sequencing
doi:10.1038/nrd3733
Researchers are starting to use high-throughput genomic technologies to guide patients into trials of experimental cancer therapies, but is our understanding of the cancer genome ready yet?
Full Text

FDA says study overestimated non-compliance with data-reporting laws
doi:10.1038/nature.2012.10549
US drug regulator finds no evident harm caused by sponsors failing to post drug-trial data.
Full Text

An audience with Stephen Frye
doi:10.1038/nrd3726
Stephen Frye, from the University of North Carolina in Chapel Hill, USA, discusses emerging capabilities of academic drug discoverers.
Full Text

Analysis

Top

Cancer cell line encyclopedias
doi:10.1038/scibx.2012.431
Two research teams have independently developed large-scale screening platforms to profile hundreds of human cancer cell lines and identify drug sensitivity biomarkers. Novartis, a member of one of the groups, is now using the platform to guide patient selection in Phase I cancer trials.
Full Text

Fresh from the Pipeline: Ivacaftor
doi:10.1038/nrd3723
First disease-modifying drug approved in the United States for the treatment of cystic fibrosis in patients with a specific mutation in the gene encoding the cystic fibrosis transmembrane conductance regulator.
Full Text

From the analyst's couch: Drug development risk and the cost of capital
doi:10.1038/nrd3722
This article analyses the relationship between risk and the cost of capital for projects in different stages of drug development and describes a framework that could improve portfolio optimization strategies.
Full Text

Research Highlights

Top

Neurodegenerative disease: The stress of misfolding
doi:10.1038/nrd3731
Two studies provide evidence that α-synuclein-induced endoplasmic reticulum (ER) stress has a crucial role in promoting neurodegeneration in α-synucleinopathies, and that targeting chronic ER stress may represent a plausible target for future therapies.
Full Text

Cancer genomics: Constructing a 'cancerpaedia'
doi:10.1038/nrd3730
Two recent papers published in Nature report on genomic changes in cancer cell lines that indicate sensitivity to targeted drugs.
Full Text

Mouse models: Of mice and men
doi:10.1038/nrc3270
A clinical trial in mice with lung cancer indicates the likely efficacy of the MEK inhibitor selumetinib in a current ongoing human clinical trial.
Full Text

Research & Reviews

Top

Epigenetic protein families: a new frontier for drug discovery
doi:10.1038/nrd3674
In this article, the authors review the protein families that mediate epigenetic signalling through histone acetylation and methylation, and highlight progress in the pharmacological modulation of each class of proteins.
Full Text

Intra-tumour heterogeneity: a looking glass for cancer?
doi:10.1038/nrc3261
This Review outlines both genetic and non-genetic causes of phenotypic heterogeneity of tumour cells and the implications of intra-tumour heterogeneity in diagnostics and the development of therapeutic resistance.
Full Text

The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma
doi:10.1038/nature11114
A transposon-mediated insertional mutagenesis screen reveals inactivation of the X-linked deubiquitinase gene Usp9x in over 50% of pancreatic ductal adenocarcinomas, suggesting Usp9x has prognostic and therapeutic relevance for this disease.
Full Text

A selective inhibitor reveals PI3Kγ dependence of TH17 cell differentiation
doi:10.1038/nchembio.957
A chemoproteomic approach adapted for high-throughput screening leads to the identification of a selective PI3Kγ inhibitor. Application of this inhibitor in human and mouse cellular models reinforces selective inhibition of PI3Kγ as a potential treatment for inflammatory and autoimmune diseases.
Full Text

Drug Discovery
JOBS of the week
Postdoc Medicinal Chemistry
Department of Drug Design, University of Groningen
Engineering Liposome-Nanoparticle Hybrid Systems for Image-Guided Drug Delivery
UCL School of Pharmacy
Postdoctoral Fellow in Computational Structure-Based Drug Design
Mount Sinai School of Medicine (Zhou Lab)
Sr. Programmer Analyst, Drug Safety
Genentech
Drug Safety Physician Job
Yoh
More Science jobs from
Drug Discovery
EVENT
7th Protein Kinases in Drug Discovery
30.-31.05.12
MA, US
More science events from

Careers

Top

Career snapshots archive
Career snapshots feature people associated with drug discovery and drug development, with the aim of providing expert insights and advice on a wide range of positions and career paths in this field.
Full Text

Top
Advertisement
SciBX: Science-Business eXchange is a weekly publication that identifies and analyzes the most important translational research articles from over 40 journals. Find out which papers have real scientific and commercial potential, and why.

Recommend SciBX to your library today.
 
nature events
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here.
Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com
More Nature Events

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount
(You will need to log in to be recognised as a nature.com registrant)

For further technical assistance, please contact our registration department

For print subscription enquiries, please contact our subscription department

For other enquiries, please contact our customer feedback department

Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA

Nature Publishing Group's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne
San Diego - San Francisco - Washington - New York - Boston

Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS.

© Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.

nature publishing group

No comments: